{"entity":{"id":"upmc-hillman","kind":"institution","name":"UPMC Hillman Cancer Center","aka":["University of Pittsburgh Cancer Institute"],"tldr":"UPMC Hillman is Pittsburgh's NCI comprehensive centre; Bernard Fisher ran the NSABP breast trials here, Yuan Chang and Patrick Moore discovered Kaposi sarcoma herpesvirus and Merkel cell polyomavirus, and its LAG-3 biology underpins the melanoma drug relatlimab.","summary":"NCI comprehensive since 1990, UPMC Hillman spans western Pennsylvania through UPMC's network. Bernard Fisher led the NSABP from Pittsburgh, proving with B-06 that lumpectomy plus radiation equals mastectomy and with P-1 that tamoxifen prevents breast cancer; NSABP lives on within NRG Oncology. Yuan Chang and Patrick Moore discovered Kaposi sarcoma herpesvirus in 1994 and Merkel cell polyomavirus in 2008. Dario Vignali's LAG-3 biology underpins relatlimab, Hassane Zarour and Diwakar Davar showed faecal microbiota transplant can overcome anti-PD-1 resistance in melanoma, and Greg Delgoffe studies T-cell metabolism in tumours. The centre also has a large head and neck cancer immunotherapy programme.","asOf":"2026-09-09","links":[{"label":"UPMC Hillman Cancer Center","url":"https://hillman.upmc.com"},{"label":"Clinical trials","url":"https://hillman.upmc.com/research/clinical-trials"}],"tags":[],"related":[],"cancers":["kaposi-sarcoma","merkel-cell-carcinoma","melanoma","head-and-neck","breast-hr-positive"],"sections":[],"technologies":["microbiome-modulation-io","gamma-knife","radiosurgery-srs","cyberknife"],"targets":["lag3"],"drugs":["tamoxifen","relatlimab-nivolumab","cetuximab"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jason-luke"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Pittsburgh, PA","country":"US","lat":40.455,"lng":-79.96,"institutionType":"cancer-center","website":"https://hillman.upmc.com","nci":"comprehensive","university":"University of Pittsburgh","programs":["Breast cancer trials (NSABP heritage)","Tumour virology","Melanoma immunotherapy and microbiome","LAG-3 biology"]},"route":"/institutions/upmc-hillman/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/"}],"technology":[{"id":"cyberknife","kind":"technology","name":"CyberKnife robotic radiosurgery","route":"/technologies/cyberknife/"},{"id":"gamma-knife","kind":"technology","name":"Gamma Knife","route":"/technologies/gamma-knife/"},{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/"},{"id":"radiosurgery-srs","kind":"technology","name":"Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)","route":"/technologies/radiosurgery-srs/"}],"target":[{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/"},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"}],"company":[{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}],"person":[{"id":"jason-luke","kind":"person","name":"Jason J. Luke","route":"/people/jason-luke/"},{"id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","route":"/people/john-kirkwood/"}],"paper":[{"id":"paper-singhi-alk-rearrangements-pancreatic-jnccn-2017","kind":"paper","name":"Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-singhi-alk-rearrangements-pancreatic-jnccn-2017/"},{"id":"paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019","kind":"paper","name":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","route":"/key-papers/paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019/"},{"id":"paper-dbouk-caps5-stage-survival-jco-2022","kind":"paper","name":"The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival","route":"/key-papers/paper-dbouk-caps5-stage-survival-jco-2022/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}]}}